Cargando…

Estimation of the Number of Brazilian Women Living With Metastatic Breast Cancer

PURPOSE: Breast cancer is the most common cancer and the leading cause of cancer-related death in women worldwide. The number of women living with metastatic breast cancer (MBC) in Brazil is unknown. The objective of this article was to use population-based data to estimate the prevalence of MBC in...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinert, Tomás, Pellegrini, Rodrigo, Rol, Rodrigo, Werutsky, Gustavo, Barrios, Carlos Henrique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051793/
https://www.ncbi.nlm.nih.gov/pubmed/32109156
http://dx.doi.org/10.1200/JGO.19.00404
_version_ 1783502736988307456
author Reinert, Tomás
Pellegrini, Rodrigo
Rol, Rodrigo
Werutsky, Gustavo
Barrios, Carlos Henrique
author_facet Reinert, Tomás
Pellegrini, Rodrigo
Rol, Rodrigo
Werutsky, Gustavo
Barrios, Carlos Henrique
author_sort Reinert, Tomás
collection PubMed
description PURPOSE: Breast cancer is the most common cancer and the leading cause of cancer-related death in women worldwide. The number of women living with metastatic breast cancer (MBC) in Brazil is unknown. The objective of this article was to use population-based data to estimate the prevalence of MBC in Brazil. METHODS: Using 4 different sources and cancer registries (DataSUS, Registro Hospitalar de Câncer, the Brazilian National Health Agency, and the National Geography and Statistics Institute) with data from 2008 to 2018, we built a database that represents Brazilian MBC cases. The current number of women in the model living with MBC was considered the prevalence (recurrent or de novo), and new cases in the year 2018 represented the incidence. In each of these outcomes, we were able to separate our population on the basis of cancer subtype, age, and time from diagnosis. RESULTS: We estimate that 44,642 women currently live with MBC in Brazil. This accounts for one in every 2,409 Brazilian women and approximately 41 women per 100,000. A total of 58% have hormone receptor–positive/human epidermal growth factor receptor 2–negative tumors, 25% are human epidermal growth factor receptor 2–positive, and 16% have triple-negative breast cancer. According to our methodology, the estimated median overall survival of Brazilian women after diagnosis of MBC is 26.2 months. CONCLUSION: The significant number of patients living with MBC should inform and raise the interest of the many stakeholders involved. This collaborative effort is a clear requirement to improve the lives of these patients as well as to prepare for future challenges related to the trend of a progressive increase in MBC prevalence.
format Online
Article
Text
id pubmed-7051793
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society of Clinical Oncology
record_format MEDLINE/PubMed
spelling pubmed-70517932020-03-03 Estimation of the Number of Brazilian Women Living With Metastatic Breast Cancer Reinert, Tomás Pellegrini, Rodrigo Rol, Rodrigo Werutsky, Gustavo Barrios, Carlos Henrique JCO Glob Oncol Original Reports PURPOSE: Breast cancer is the most common cancer and the leading cause of cancer-related death in women worldwide. The number of women living with metastatic breast cancer (MBC) in Brazil is unknown. The objective of this article was to use population-based data to estimate the prevalence of MBC in Brazil. METHODS: Using 4 different sources and cancer registries (DataSUS, Registro Hospitalar de Câncer, the Brazilian National Health Agency, and the National Geography and Statistics Institute) with data from 2008 to 2018, we built a database that represents Brazilian MBC cases. The current number of women in the model living with MBC was considered the prevalence (recurrent or de novo), and new cases in the year 2018 represented the incidence. In each of these outcomes, we were able to separate our population on the basis of cancer subtype, age, and time from diagnosis. RESULTS: We estimate that 44,642 women currently live with MBC in Brazil. This accounts for one in every 2,409 Brazilian women and approximately 41 women per 100,000. A total of 58% have hormone receptor–positive/human epidermal growth factor receptor 2–negative tumors, 25% are human epidermal growth factor receptor 2–positive, and 16% have triple-negative breast cancer. According to our methodology, the estimated median overall survival of Brazilian women after diagnosis of MBC is 26.2 months. CONCLUSION: The significant number of patients living with MBC should inform and raise the interest of the many stakeholders involved. This collaborative effort is a clear requirement to improve the lives of these patients as well as to prepare for future challenges related to the trend of a progressive increase in MBC prevalence. American Society of Clinical Oncology 2020-02-28 /pmc/articles/PMC7051793/ /pubmed/32109156 http://dx.doi.org/10.1200/JGO.19.00404 Text en © 2020 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/
spellingShingle Original Reports
Reinert, Tomás
Pellegrini, Rodrigo
Rol, Rodrigo
Werutsky, Gustavo
Barrios, Carlos Henrique
Estimation of the Number of Brazilian Women Living With Metastatic Breast Cancer
title Estimation of the Number of Brazilian Women Living With Metastatic Breast Cancer
title_full Estimation of the Number of Brazilian Women Living With Metastatic Breast Cancer
title_fullStr Estimation of the Number of Brazilian Women Living With Metastatic Breast Cancer
title_full_unstemmed Estimation of the Number of Brazilian Women Living With Metastatic Breast Cancer
title_short Estimation of the Number of Brazilian Women Living With Metastatic Breast Cancer
title_sort estimation of the number of brazilian women living with metastatic breast cancer
topic Original Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051793/
https://www.ncbi.nlm.nih.gov/pubmed/32109156
http://dx.doi.org/10.1200/JGO.19.00404
work_keys_str_mv AT reinerttomas estimationofthenumberofbrazilianwomenlivingwithmetastaticbreastcancer
AT pellegrinirodrigo estimationofthenumberofbrazilianwomenlivingwithmetastaticbreastcancer
AT rolrodrigo estimationofthenumberofbrazilianwomenlivingwithmetastaticbreastcancer
AT werutskygustavo estimationofthenumberofbrazilianwomenlivingwithmetastaticbreastcancer
AT barrioscarloshenrique estimationofthenumberofbrazilianwomenlivingwithmetastaticbreastcancer